Clinical trial
Nintedanib Treatment in Unicentric Castleman Disease
NCT06643091 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Nintedanib Treatment in Unicentric Castleman Disease
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 1, 2024
- Completion date
- September 1, 2030
- Enrollment
- 13 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.